BindingDB PrimarySearch

Found 2 hits Enz. Inhib. hit(s) with Target = 'Interleukin-2' and Ligand = 'BDBM161903'
Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	k_off s^-1	k_on M^-1s^-1	pH	Temp °C
Interleukin-2 (Homo sapiens (Human))	BDBM161903 (US9682976, 322 \| US9682976, 323) Show SMILES Show InChI	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	n/a	n/a	<1.00E+4	n/a	n/a	n/a	n/a
Rigel Pharmaceuticals, Inc. US Patent					Assay Description Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...				US Patent US9682976 (2017) BindingDB Entry DOI: 10.7270/Q2DJ5CT2
Rigel Pharmaceuticals, Inc. US Patent					More data for this Ligand-Target Pair
Interleukin-2 (Homo sapiens (Human))	BDBM161903 (US9682976, 322 \| US9682976, 323) Show SMILES Show InChI	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	n/a	n/a	<500	n/a	n/a	n/a	n/a
Rigel Pharmaceuticals, Inc. US Patent					Assay Description Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...				US Patent US9682976 (2017) BindingDB Entry DOI: 10.7270/Q2DJ5CT2
Rigel Pharmaceuticals, Inc. US Patent					More data for this Ligand-Target Pair